KING OF PRUSSIA, Pa.,
Dec. 4, 2014 /PRNewswire/ -- CSL
Behring's parent company CSL Limited (ASX: CSL) has issued its
annual corporate responsibility report – "Our Corporate
Responsibility 2014." The report details the global
biopharmaceutical company's performance across key priority areas
from July 1, 2013 through
June 30, 2014 – recording another
strong performance led by CSL Behring.
The company has consistently achieved growth through the
disciplined execution of its business strategy – investing in
research and development to advance therapies for unmet medical
needs, growing its core portfolio of products by expanding
indications and markets, and a relentless commitment to
productivity and efficiency.
CSL Limited CEO and Managing Director Paul Perreault emphasizes that people are the
driving force behind the company's strong performance. "People are
our greatest asset, and the ability to create a safe and rewarding
environment filled with opportunities for our people is critical.
So, too, is our unwavering focus on placing the needs of patients
at the core of all that we do.
"Ensuring we can continue to provide lifesaving and
life-enhancing therapies requires us to believe, think and act in a
responsible and sustainable way. I am pleased to introduce Our
Corporate Responsibility 2014 report, which illustrates
our ongoing commitment with tangible examples."
Highlights of CSL's economic, social and environmental
performance include:
- Economic contribution direct to local economies of US$4.9 billion, a 5% increase on the previous
year, including global community investment of US$32.8 million to patient, biomedical and local
communities;
- Research and Development investment of US$466 million with more than 40 clinical studies
in operation across the pipeline – 22 product
registrations/indications for serious diseases in various markets,
an increase on the previous year;
- 179 GMP regulatory audits of our manufacturing facilities with
no impact on product marketing licenses;
- Second consecutive year of 7% growth in the total workforce,
reaching 13,468 employees as of June 30,
2014;
- Health and safety performance saw lost time due to injury
(LTIFR), lost days (DLFR) and incidences of medical treatment
(MTIFR) reduced by 20%, 30% and 12%, respectively;
- Maintained compliance with environmental laws and regulations
across global operations;
- Despite an expanding facility footprint, CSL experienced
moderate increases in absolute numbers across environmental
indicators;
- Commenced an enterprise-wide climate change risk assessment,
taking into consideration updated observations and forecasts from
the United Nations Intergovernmental Panel on Climate Change
(IPCC).
To view the complete "Our Corporate Responsibility
2014" report, click here. CSL invites stakeholders to
provide feedback on its report via an anonymous survey
(https://www.surveymonkey.com/s/F839KMG). For the first 150
responses, CSL will donate US $50 per
survey to the World Federation of Hemophilia.
About CSL Limited
Headquartered in Melbourne, Australia, CSL Limited (ASX: CSL)
is a global biopharmaceutical company that develops, manufactures
and markets biotherapies to prevent and treat rare and serious
human diseases. CSL owns major facilities in Australia, Germany, Switzerland and the US, and employs over
13,000 people in more than 27 countries.
About CSL Behring
CSL Behring is a leader in the
plasma protein therapeutics industry. Committed to saving lives and
improving the quality of life for people with rare and serious
diseases, the company manufactures and markets a range of
plasma-derived and recombinant therapies worldwide.
CSL Behring therapies are used around the world to treat
coagulation disorders including hemophilia and von Willebrand
disease, primary immune deficiencies, hereditary angioedema and
inherited respiratory disease, and neurological disorders in
certain markets. The company's products are also used in cardiac
surgery, organ transplantation, burn treatment and to prevent
hemolytic diseases in the newborn.
CSL Behring operates one of the world's largest plasma
collection networks, CSL Plasma. CSL Behring is a global
biopharmaceutical company and a member of the CSL Group of
companies. The parent company, CSL Limited (ASX: CSL), is
headquartered in Melbourne,
Australia.
Contact:
Chris Florentz
610-878-4316
Christopher.Florentz@cslbehring.com
Logo -
http://photos.prnewswire.com/prnh/20100914/PH63692LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/csl-issues-our-corporate-responsibility-2014-report-300004444.html
SOURCE CSL Behring